Brain tumor and seizures: Pathophysiology and its implications for treatment revisited

Epilepsia

Volumn 44, Issue 9, 2003, Pages 1223-1232

  Schaller, Bernhard ^a,c   Rüegg, Stephan J ^b  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antiepileptic drugs; Brain tumor; Pathophysiology; Seizures; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AMINO ACID ANALYSIS; BRAIN TUMOR; DISEASE ASSOCIATION; FOCAL EPILEPSY; GLIA CELL; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; METASTASIS; NERVE CELL; PATHOPHYSIOLOGY; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RISK FACTOR; SEIZURE; TREATMENT INDICATION; TUMOR GROWTH;

ANIMALS; ANTICONVULSANTS; BRAIN NEOPLASMS; HUMANS; SEIZURES;

EID: 0042415676     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2003.05203.x     Document Type: Review

References (86)

1. Liigant A, Haldre S, Oun A, et al. Seizure disorders in patients with brain tumors. Eur Neurol 2001;45:46-51.
2. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neurol Oncol 2002;4:278-99.
3. Clusmann H, Schramm J, Kral T, et al. Prognostic factors and outcome after different parts of resection for temporal lobe epilepsy. J Neurosurg 2002;97:1131-41.
4. Tan B, Piwinica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000;12:450-8.
5. Whittle IR, Beaumont A. Seizures in patients with supratentorial oligodendroglial tumors: clinicopathological features and management considerations. Acta Neurochir 1995;135:19-24.
6. Engle J, Pedley TA, eds. Epilepsy. a comprehensive textbook. Vol 1. Philadelphia: Lippincott- Raven, 1997:Section 2.
7. Goldring S, Rich KM, Picker S. Experience with gliomas in patients presenting with chronic seizure disorder. Clin Neurosurg 1986;33:15-42.
8. Alger JR, Frank JA, Bizzi A, et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990;177:633-41.
9. Kim JH, Guimaraes PO, Shen MY, et al. Hippocampal neuronal density in temporal lobe epilepsy with and without gliomas. Acta Neuropathol (Berl) 1990;80:41-5.
10. + current in hippocampal CA1 pyramidal neurons: implications in epileptogenesis. J Neurophysiol 2001;86:2878-86.
11. Bordey A, Sontheimer H. Electrophysiological properties of human astrocytic tumor cells in situ: enigma of spiking glial cells. J Neurophysiol 1998;79:2782-93.
12. Jabs R, Paterson IA, Walz W. Qualitative analysis of membrane currents in glial cells from normal and gliotic tissue in situ: down regulation of Na+ current and lack of P2 purinergic responses. Neuroscience 1997;81:847-60.
13. McNamara JO. Emerging insights into the genesis of epilepsy. Nature 1999;399(suppl A):15-22.
14. Haglund MM, Berger MS. Kunkel DD, et al. Changes in gamma aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J Neurosurg 1992;77:209-16.
15. Mclnyre DC, Hutcheon B, Schwabe K, et al. Divergent GABA(A) receptors mediated synaptic transmission in genetically seizure prone and seizure resistant rats. J Neurosci 2002;22:9922-31.
16. Steriade M, Amzica F. Intracellular study of excitability in the seizure prone neocortex in vivo. J Neurophysiol 1999;82:3108-22.
17. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue potential exploitation for the treatment of cancer. Cancer Res 1996;56:1194-8.
18. Ranson BR. Glial modulation of neuronal excitability mediated by extracellular pH: a hypothesis. Prog Brain Res 1992;94:37-47.
19. , Church J, McLennan H. Electrophysiological properties of rat CA1 pyramidal neurons in vitro, modified by changes in extracellular bicarbonate. J Physiol 1989;415:85-108.
20. Pasternack M, Bountra C, Voipio J, et al. Influence of extracellular and intracellular pH on conductase in crayfish muscle fibers. Neuroscience 1992;47:921-9.
21. Pastemack M, Rydqvist B, Kaila K. GABA gated anion channels in intact crayfish opener muscle fibers and stretch receptor neurons are neither activated nor desensitized by glutamate. J Comp Physiol 1992;170:521-4.
22. Cadoux-Hudson TA, Blacktedge MJ, Rajagopalan B, et al. Human primary brain tumor metabolism in vivo: a phosphorus magnetic resonance spectroscopy study. Br J Cancer 1989;60:430-6.
23. Avoli M, Drapeau C, Louvel J, et al. Epileptiform activity induced by low extracellular magnesium in the human cortex maintained in vitro. Ann Neurol 1991;30:589-96.
24. Singh R, Pathak DN. Lipid peroxidation and glutathione peroxidase, glutathione reductase, superoxide dismutase, catalase and glucose-6 phosphate dehydrogenase activities in FeC13 induced epileptogenic foci in the 3-rat brain. Epilepsia 1990;31:15-26.
25. van den Pol AN, Finkbeiner SM, Cornell-Bell AH. Calcium excitability and oscillations in suprachiasmatic nucleus neurons and glia in vitro. J Neurosci 1992;12:2648-64.
26. Amzica F. In vivo electrophysiological evidence for cortical neuroglial interactions during slow (<1 Hz) and paroxysmal sleep oscillations. J Physiol (Paris) 2002;96:209-19.
27. Köhling R. GABA becomes exciting. Science 2002;298:1350-1.
28. Hamberger A, Nystrom B, Larsson S, et al. Amino acids in the neuronal microenvironment of focal human epileptic lesions. Epilepsy Res 1991;9:32-43.
29. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitoxicity and clearance of glutamate. Neuron 1996;16:675-86.
30. Wolf HK, Roos D, Blumcke I, et al. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol (Berl) 1996;91:376-84.
31. Yan QS, Jobe PCX, Bailey JW. Thalamic deficiency in norepinephrine release detected via intracerebral microdialysis: a synaptic determinant of seizure predisposition in the genetically epilepsy prone rat. Epilepsy Res 1993;14:229-36.
32. Neuman RS, Thompson PM. Serotonin mediates suppression of focal epileptiform activity induced by noxious stimulation. Epilepsia 1989;30:207-313.
33. Goldstein DS, Nadi NS, Stull R, et al. Levels of catechols in epileptogenic and nonepileptogenic regions of the human brain. J Neurochem 1988;50:225-9.
34. Olson JM, McNeel W, Young AB, et al. Localization of the peripheral type benzodiazepine binding site to mitochondria of human glioma cells. J Neuro Oncol 1992;13:35-42.
35. Bateman DE, Hardy JA, McDermott JR, et al. Amino acid transmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol Res 1988;10:112-4.
36. Ernestus RI, Rohn G, Schröder R, et al. Polyamine metabolism in brain tumors: diagnostic relevance of quantitative biochemistry. J Neurol Neurosurg Psychiatry 2001;71:88-92.
37. Sessa A, Broglia E, Terreni MR, et al. Spermidine acetylation in N1 and N8 position in rat brain and N-ethyl-N-nitrosourea induced gliomas. Cancer Lett 1994;76:121-5.
38. Laschet J, Trottier S, Grisar T, et al. Polyamine metabolism in epileptic cortex. Epilepsy Res 1992:12:151-6.
39. Subramaniam S, O'Connor MJ, Masukawa LM, et al. Polyamine effects on the NMDA receptor in human brain. Exp Neurol 1994;130:323-30.
40. 3H) kainic acid binding to brain membranes: a reevaluation of ligand potency and selectivity. J Pharmacol Toxicol Methods 1999;42:121-5.
41. Sherwin A, Robitaille Y, Quesney F, et al. Excitatory amino acids are elevated in human epileptic cerebral cortex. Neurology 1988;38:920-3.
42. A-receptor mediated oscillations. J Neurosci 2000;20:6820-9.
43. McBain CJ. A short-term mechanism of plasticity for interneurons? J Physiol (London) 1998;511:311.
44. Mody I, Heinemann U. NMDA receptors of dentate gyrus granule cells participate in synaptic transmission following kindling. Nature 1987;326:701-4.
45. Lynch M, Sayin U, Glorai G, et al. NMDA receptor dependent plasticity of granule cell spiking in the dentate gyrus of normal and epileptic rats. J Neurophysiol 2000;84:2868-79.
46. Continho V, Knopfel T. Metabotropic glutamate receptors: electrical and chemical signaling properties. Neuroscientist 2002;8:551-61.
47. Dietrich D, Kral T, Clusmann H, et al. Presynaptic group II metabotropic glutamate receptors reduce stimulated and spontaneous transmitter release in human dentate gyrus. Neuropharmacology 2002;42:297-305.
48. Rutecki PA, Sayin U, Yang Y, et al. Determinant of ictal epileptiform patterns in the hippocampal slice. Epilepsia 2002;43(suppl 5):S179-83.
49. Tizzano JP, Griffey BI, Schoepp DD. Induction or protection of limbic seizures in mice by mGlu R subtype selective agonists. Neuropharmacology 1995;34:1063-7.
50. Aronica E, van Vliet EA, Mayboroda OA, et al. Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. Eur J Neurosci 2000;12:2333-44.
51. Ferraguti F, Corti C, Valerio E, et al. Activated astrocytes in areas of kainite induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5. Exp Brain Res 2001;137:1-11.
52. Kim E, Lowenson JD, MacLaren DC, et al. Deficiency of a protein repair enzyme results in the accumulation of altered protein, retardation of growth, and fatal seizures in mice. Proc Natl Acad Sci USA 1997;94:6132-7.
53. Mangoura D, Sakellaridis N, Jones J, et al. Early and late passage C6 glial cell growth: similarities with primary glial cells in culture. Neurochem Res 1989;14:941-7.
54. Dutuit M, Didier Bazes M, Vergnes M, et al. Specific alteration in the expression of glial fibrillary acidic protein, glutamate dehydrogenase, and glutamine synthetase in rats with genetic absence epilepsy. Glia 2000;32:15-24.
55. Guye M, LeFur Y, Confort Gouny S, et al. Metabolic and electrophysiological alterations in subtypes of temporal lobe epilepsy: a combined proton magnetic resonance spectroscopic imaging and depth electrodes study. Epilepsia 2002;43:1197-209.
56. Jenneman R, Rodden A, Bauer BL, et al. Glycosphingolipids of human gliomas. Cancer Res 1990;50:7444-9.
57. Murakami M, Ushito Y, Mihara Y, et al. Cholesterol uptake by human glioma cells via receptor-mediated endocytosis of low-density lipoproteins. J Neurosurg 1990;73:760-7.
58. Louw DF, Bose R, Sima AA, et al. Evidence for high-free radical state in low-grade astrocytomas. Neurosurgery 1997;41:1146-50.
59. Strange RC, Fryer AA, Matharoo B, et al. The human glutathione S transferase: comparison of isoenzyme expression in normal and astrocytic brain. Biochim Biophys Acta 1992;1139:222-8.
60. Awad IA, Rosenfeld J, Ahl J, et al. Intractable epilepsy and structural lesions of the brain: mapping, resection strategies and seizure outcome. Epilepsia 1991;32:179-86.
61. Chao CC, Molitor TW, Hu S. Neuroprotective role of IL-4 against activated microglia. J Immunol 1993;151:1473-81.
62. Soliven B, Albert J. Tumor necrosis factor modulates the inactivation of catecholamine secretion in cultured sympathetic neurons. J Neurochem 1992;58:1073-8.
63. Powell EM, Campell DB, Stanwood GD, et al. Genetic disruption of cortical interneuron development causes region and GABA cell type specific deficits, epilepsy, and behavioral dysfunction. J Neurosci 2003;15:622-31.
64. Vezzani A, Moneta D, Richichi C, et al. Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 2002;43(suppl 5):S30-5.
65. Fonseca GG, Green CR, Nicholson LF. Upregulation in astrocytic connexin 43 gap junction-levels may exacerbate generalized seizures in mesial temporal lobe epilepsy. Brain Res 2002;929:105-16.
66. Aronica E, Groter JA, Jansen GH, et al. Expression of connexin 43 and connexin 32 gap junction proteins in epilepsy associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol (Berl) 2001;101:449-59.
67. Hatten ME, Liem RK, Shelansik ML, et al. Astroglia in CNS injury. Glia 1991;4:233-43.
68. Hossain MZ, Peerling J, Sutherland GR, et al. Ischemia induced cellular redistribution of the astrocytic gap junctional protein connexin 43 in rat brain. Brain Res 1994;652:311-22.
69. Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002;14:299-307.
70. Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumors. Acta Neurochir (Wien) 1990;103:47-51.
71. Shaw MD. Post-operative epilepsy and the efficacy of anticonvulsant therapy. Acta Neurochir (Wien) 1990;50(suppl):S55-7.
72. North JB, Penhall RK, Hanieh A, et al. Phenytoin and postoperative epilepsy: a double-blind study. J Neurosurg 1983;58:672-7.
73. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 2000;54:1886-93.
74. Dichter MA. Mechanisms of action of new antiepileptic drugs. Adv Neurol 1998;76:1-9.
75. Cohen N, Strauss G, Lew R, et al. Should prophylactic anticonvulsants be administered to patients with newly diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988;6:1621-4.
76. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7-14.
77. Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31.
78. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8.
79. Rogawski MA. Does P-glycoprotein play a role in pharmacoresistance to antiepileptic drugs? Epilepsy Behav 2002;3:493-5.
80. Ramachandran V, Shorvon SD. Clues to the genetic influences of drug responsiveness in epilepsy. Epilepsia 2003;44(suppl 1):S33-7.
81. Goldman B. Multidrug resistance: can new drugs help chemotherapy score against cancer? J Natl Cancer Inst 2003;94:255-7.
82. Bittigau P, Sifringer M, Genz K, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA 2002;99:15089-94.
83. Kim R, Tanabe K, Uchida Y, et al. Current status of the molecular mechanisms of anticancer drug-induced apoptosis: the contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 2002;50:343-52.
84. Blaheta RA. Cinatl J Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002;22:492-511.
85. Li X, Ketter TA, Frye MA. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Dis 2002;69:1-14.
86. Striano S, Stfiano P, Boccella P, et al. Tiagabine in glial tumors. Epilepsy Res 2002;49:81-5.